Navigation Links
Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/4/2008

SAN FRANCISCO, Nov. 4 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biopharmaceutical company, today announced that David H. Kirn, M.D., President and Chief Executive Officer, will present an overview of the Company at the 10th Annual Rodman & Renshaw Healthcare Conference in New York on November 11, 2008 at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) at the Palace Hotel, New York.

A webcast of the presentation will be available during the event at http://www.jennerex.com and will be archived and available on the website for 3 months.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
2. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
3. Alexion to Present at Investor Conferences
4. IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference
5. Jazz Pharmaceuticals to Present at Investor Conferences
6. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
7. XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11
8. The Quantum Group Inc. To Present at Paulson Investments 31st Annual Westergaard Conference
9. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
10. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
11. BD to Present at Investor Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... ... 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit area ... owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry for ... The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged families ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just two days, Aqua ... micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the ... consumers (and counting) already backing the campaign. , “We are very grateful ...
(Date:3/24/2017)... Northridge, CA (PRWEB) , ... March 24, 2017 ... ... Dr. Ramin Assili, announce that they are now offering treatments for sleep apnea ... treated at dental offices. Sleep apnea , specifically the obstructive type, is ...
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017   The Accreditation Council for ... affairs in the pharmaceutical industry has appointed Dr. ... a newly formed scientific advisory board. Dr. Chin ... the first ever medical affairs think tank within ... about the ACMA, please visit  www.medicalaffairsspecialist.org .  ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
Breaking Medicine Technology: